A Phase 1/2 interventional study of Selpercatinib in Medullary Thyroid Cancer, Infantile Myofibromatosis and Infantile Fibrosarcoma, sponsored by Eli Lilly and Company. Active, not recruiting at 26 sites in 11 countries. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.
Among the 81 studies in Carcinoma, Medullary with a site in United States, this one is the 27th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2019, is one of 11 in phase 1/2, reaches primary completion later than 3 of the 22 other live ones, and was the 59th registered.
144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.
Browse Carcinoma, Medullary studies →12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Japan and 1 more country
Ages 18–100
University of Arizona · Sites in United States
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 6 Months to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 35 · Phase 3 4 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is above the median of 30 across 100 interventional studies indexed under Carcinoma, Medullary.
Median enrollment 30 across the 66 interventional studies, 413 across the 10 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 81 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 5 studies filed under Carcinoma, Medullary — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Medullary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259304University of Southern CaliforniaSocial Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | 2026-12-31 |
| NCT07713901Novo Nordisk A/SDatabase Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | 2026-12-31 |
| NCT04467021ECOG-ACRIN Cancer Research GroupCancer and Blood Pressure Management, CARISMA Study | 2027-08-31 |
| NCT04759911M.D. Anderson Cancer CenterSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Carcinoma, Medullary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, participants will be enrolled using a rolling 6 dose escalation scheme. The starting dose of LOXO-292 is equivalent to the adult recommended phase 2 dose of 160 milligrams (mg) twice a day (BID). Once the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) is identified, participants will be enrolled to one of four phase 2 dose expansion cohorts depending on tumor histology and tumor genotype. Cycle length will be 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this cohort had MTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.
Drug: Selpercatinib
Participants in this cohort had PTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.
Drug: Selpercatinib
Participants in this cohort had other (REarranged during Transfection (RET)-altered non-thyroid) cancer and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.
Drug: Selpercatinib
Oral LOXO-292
Also known as: LOXO-292, LY3527723
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development. * G3 vomiting/diarrhea was DLT only if it persists \>48 h despite standard of care treatment. * G4 vomiting/diarrhea was DLT regardless of duration. * Any toxicity, regardless of the NCI CTCAE v5.0 grade, resulting in discontinuation or dose reduction of treatment (except symptoms related to progressive disease (PD)). * G4/G3 thrombocytopenia with G1 or higher bleeding. * G4 anemia lasting \>8 days, despite supportive therapy. * G4 neutropenia, lasting \>8 days, despite supportive therapy
Time frame: Cycle 1 (28 Day Cycle)
Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study
ORR: Percentage of participants who achieve best overall response Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Time frame: Date of first dose to disease progression or death (Up to 62.4 Months)
Plasma Concentrations of LOXO-292
Outcome data will be provided after the study is completed.
Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)
Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of LOXO-292
Outcome data will be provided after the study is completed.
Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)
Maximum Concentration (Cmax) of LOXO-292
Outcome data will be provided after the study is completed.
Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)
Time to Maximum Concentration (Tmax) of LOXO-292
Outcome data will be provided after the study is completed.
Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)
Recommended LOXO-292 Dose for Phase 2 (MTD)
Outcome data will be provided after the study is completed.
Time frame: Cycle 1 (28 days)
To Assess the Preliminary Anti-Tumor Activity of LOXO-292 in Pediatric Participants With Tumors Harboring an Activating RET Alteration as Determined by ORR Based on RECIST v1.1
Outcome data will be provided after the study is completed.
Time frame: Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)
Changes From Baseline in Pain Measures as Measured by Wong Baker Faces Scales. Wong-Baker Faces Pain Scale Includes Pictures of Facial Expressions With Correlating Scores of 0 Being 'no Hurt' and 10 Being 'Hurts Worst'.
Outcome data will be provided after the study is completed.
Time frame: Up to 24 months
Changes From Baseline in Health Related Quality of Life Measures as Measured by Pediatric Quality of Life (PedsQoL) Inventory Core. PedsQoL Includes a List of Problems With Scores of 0 Being 'Never a Problem' and 4 Being 'Almost Always a Problem'.
Outcome data will be provided after the study is completed.
Time frame: Up to 24 months
Objective Response Rate as Assessed by RECIST v1.1, as Assessed by Investigator
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Objective Response Rate as Assessed by RANO, as Assessed by Investigator
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Duration of Response (DOR) as Assessed by Investigator
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Duration of Response (DOR) as Assessed by the IRC
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Progression Free Survival (PFS) as Assessed by Investigator
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
PFS as Assessed by IRC
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Overall Survival (OS)
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Clinical Benefit Rate (by Investigator)
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Clinical Benefit Rate (by IRC)
Outcome data will be provided after the study is completed.
Time frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.
Frequency of Adverse Events (AEs)
Outcome data will be provided after the study is completed.
Time frame: From the time of informed consent, for approximately 24 months (or earlier if the participants discontinues from the study), and through Safety Follow-up (28 days after the last dose)
To Evaluate the Concordance of Prior Molecular That Detected a RET Alteration Within the Participant's Tumor With Diagnostic Tests Being Evaluated by Sponsor
Outcome data will be provided after the study is completed.
Time frame: 6 months
Phase 2: Post-Operative Stage on Participants Treated With LOXO-292
Tumor stage is described according to the Tumor, Node, Metastasis (TNM)Classification of malignant tumors of the Union for International Cancer Control (UICC). Outcome data will be provided after the study is completed.
Time frame: Up to 3 years
Phase 2: Surgical Margin Status in Participants Treated With LOXO-292
Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor. Outcome data will be provided after the study is completed.
Time frame: Up to 3 years
Descriptive Analysis of Pretreatment Surgical Plan
Outcome data will be provided after the study is completed.
Time frame: Up to 3 years
Descriptive Analysis of Post-Treatment Plans
Outcome data will be provided after the study is completed.
Time frame: Up to 3 years
The study consisted of two parts: Phase 1 (dose-escalation) and Phase 2 (dose-expansion). In Phase 1, three participants received selpercatinib, with dosing based on body surface area. The starting dose level was 92 mg/m\^2 (maximum 160 mg, twice daily (BID\]), selected to approximate the exposure associated with the recommended Phase 2 dose (RP2D) in adults. The Phase 2 portion opened for enrollment after confirmation of the RP2D of 92 mg/m\^2 (maximum 160 mg BID).
| Milestone | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): Medullary Thyroid Cancer (MTC) Group | Cohort 2 (Phase 2): Papillary Thyroid Cancer (PTC) Group | Cohort 3 (Phase 2): Other Cancer Group |
|---|---|---|---|---|
| Started | 3 | 0 | 0 | 0 |
| Completed | 3 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): Medullary Thyroid Cancer (MTC) Group | Cohort 2 (Phase 2): Papillary Thyroid Cancer (PTC) Group | Cohort 3 (Phase 2): Other Cancer Group |
|---|---|---|---|---|
| Started | 0 | 15 | 15 | 6 |
| Received at least 1 dose of study drug | 0 | 15 | 15 | 6 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 15 | 15 | 6 |
| Withdrew: Ongoing treatment | 0 | 13 | 14 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development. * G3 vomiting/diarrhea was DLT only if it persists \>48 h despite standard of care treatment. * G4 vomiting/diarrhea was DLT regardless of duration. * Any toxicity, regardless of the NCI CTCAE v5.0 grade, resulting in discontinuation or dose reduction of treatment (except symptoms related to progressive disease (PD)). * G4/G3 thrombocytopenia with G1 or higher bleeding. * G4 anemia lasting \>8 days, despite supportive therapy. * G4 neutropenia, lasting \>8 days, despite supportive therapy
| Participants | Dose Escalation Cohort (Phase 1) |
|---|---|
| Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 |
ORR: Percentage of participants who achieve best overall response Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
| Percentage of participants | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group |
|---|---|---|---|
| Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study | 60.0 | 53.3 | 33.3 |
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Tumor stage is described according to the Tumor, Node, Metastasis (TNM)Classification of malignant tumors of the Union for International Cancer Control (UICC). Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor. Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Collected over Baseline up to 64 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: MTC Group | 0/15 (0%) | 8/15 (53.3%) | 15/15 (100%) |
| Cohort 2: PTC Group | 0/15 (0%) | 4/15 (26.7%) | 15/15 (100%) |
| Cohort 3: Other Cancer Group | 4/6 (66.7%) | 3/6 (50%) | 5/6 (83.3%) |
| Event | Cohort 1: MTC Group | Cohort 2: PTC Group | Cohort 3: Other Cancer Group |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/15 | 0/15 | 1/6 |
| Gastrointestinal fistulaGastrointestinal disorders | 0/15 | 0/15 | 1/6 |
| Drug hypersensitivityImmune system disorders | 0/15 | 0/15 | 1/6 |
| Abdominal infectionInfections and infestations | 0/15 | 0/15 | 1/6 |
| SepsisInfections and infestations | 0/15 | 0/15 | 1/6 |
| VomitingGastrointestinal disorders | 2/15 | 0/15 | 0/6 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/15 | 0/6 |
| AscitesGastrointestinal disorders | 0/15 | 1/15 | 0/6 |
| ConstipationGastrointestinal disorders | 1/15 | 0/15 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 0/15 | 0/6 |
| Event | Cohort 1: MTC Group | Cohort 2: PTC Group | Cohort 3: Other Cancer Group |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/15 | 10/15 | 2/6 |
| VomitingGastrointestinal disorders | 9/15 | 2/15 | 0/6 |
| NauseaGastrointestinal disorders | 8/15 | 5/15 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 8/15 | 2/15 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 3/15 | 8/15 | 3/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/15 | 2/15 | 0/6 |
| HeadacheNervous system disorders | 8/15 | 4/15 | 0/6 |
| Abdominal painGastrointestinal disorders | 4/15 | 4/15 | 3/6 |
| PyrexiaGeneral disorders | 7/15 | 4/15 | 3/6 |
| Alanine aminotransferase increasedInvestigations | 4/15 | 5/15 | 3/6 |
All participants who received at least one dose of study drug. The Baseline data were planned to be presented according to Phases. Here "number analyzed" signifies participants who were evaluable for specified Phase of the study.
| Age, Customized(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group | Total |
|---|---|---|---|---|---|
| Age — <=18 years | 2 | 10 | 13 | 5 | 30 |
| Age — Between 18 and 65 years | 1 | 3 | 2 | 0 | 6 |
| Sex: Female, Male(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group | Total |
|---|---|---|---|---|---|
| Female | 2 | 5 | 7 | 3 | 17 |
| Male | 1 | 8 | 8 | 2 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 4 | 0 | 7 |
| Not Hispanic or Latino | 0 | 11 | 11 | 4 | 26 |
| Unknown or Not Reported | 0 | 2 | 0 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 7 | 3 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 2 |
| White | 3 | 9 | 6 | 0 | 18 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 | 2 | 6 |
| Region of Enrollment(Participants) | Dose Escalation Cohort (Phase 1) | Cohort 1 (Phase 2): MTC Group | Cohort 2 (Phase 2): PTC Group | Cohort 3 (Phase 2): Other Cancer Group | Total |
|---|---|---|---|---|---|
| Canada | 0 | 2 | 2 | 1 | 5 |
| South Korea | 0 | 0 | 4 | 2 | 6 |
| United States | 3 | 3 | 4 | 1 | 11 |
| Japan | 0 | 0 | 2 | 1 | 3 |
| Denmark | 0 | 1 | 0 | 0 | 1 |
| Italy | 0 | 0 | 2 | 0 | 2 |
| France | 0 | 1 | 0 | 0 | 1 |
| Australia | 0 | 4 | 0 | 0 | 4 |
| Germany | 0 | 2 | 0 | 0 | 2 |
| Spain | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Nov 2024, 64 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib